Capricor Therapeutics (CAPR) Capital Expenditures (2012 - 2026)

Capricor Therapeutics' Capital Expenditures history runs 14 years deep, the most recent figure standing at $5.1 million for Q1 2026.

• On a quarterly basis, Capital Expenditures rose 471.61% year-over-year to $5.1 million in Q1 2026; TTM through Mar 2026 was $7.1 million, a 390.28% increase from a year earlier, with the FY2025 full-year figure at $2.9 million, up 148.91% from the prior year.
• Capital Expenditures grew to $5.1 million in Q1 2026 per CAPR's latest filing, from $1.7 million in the prior quarter.
• Across five years, Capital Expenditures topped out at $5.1 million in Q1 2026 and bottomed at $9145.0 in Q3 2024.
• The 5-year median for Capital Expenditures is $488798.0 (2024), against an average of $735584.9.
• Across the five-year window, Capital Expenditures soared 1437.75% in 2022 and sank 96.61% in 2024, its largest moves.
• Year by year, Capital Expenditures stood at $694044.0 in 2022, then slipped by 19.51% to $558604.0 in 2023, then slipped by 12.5% to $488798.0 in 2024, then soared by 240.61% to $1.7 million in 2025, then soared by 207.63% to $5.1 million in 2026.
• Per Business Quant, the three latest CAPR Capital Expenditures figures stand at $5.1 million (Q1 2026), $1.7 million (Q4 2025), and $55843.0 (Q3 2025).